AA
SGNT

AlphaMark Advisors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

AlphaMark Advisors’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-32,775
Closed -$762K – 308
2015
Q1 		$762K Buy
32,775
+5,425
+20% +$144K 0.43% 65
2014
Q4 		$687K Buy
+27,350
New +$802K 0.42% 48

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AlphaMark Advisors's SGNT Position: Q2 2015 in Review

AlphaMark Advisors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2015, closing a stake of 32,775 shares — an estimated $762K sold.

AlphaMark Advisors first reported a position in SGNT in Q4 2014 and held it in 2 quarters. The position peaked at $762K in Q1 2015. 136 funds tracked by Wall St. Rank hold SGNT as of Q2 2015.

  • AlphaMark Advisors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • AlphaMark Advisors sold 32,775 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2015, an estimated $762K.
  • AlphaMark Advisors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2014 and held it in 2 quarters.
  • AlphaMark Advisors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $762K in Q1 2015.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2015.

Based on AlphaMark Advisors's 13F filing for Q2 2015, filed 11 Aug 2015.